Table 2.
Univariable and multivariable comparisons between demographics, comorbidities, treatments, and serum laboratory values for cancer patients stratified by probability of fibrosis as determined by APRI
| Variable | Low probability (n = 197) | Other (n = 82) | Univariable p | Multivariable p | OR [95 % CI] |
|---|---|---|---|---|---|
| Demographics and comorbidities | |||||
| Age (years), mean ± SE | 58.8 ± 0.8 | 59.9 ± 1.3 | 0.43 | – | – |
| Female, n (%) | 113 (57.4) | 43 (52.4) | 0.45 | – | – |
| Ethnicity, n (%) | 0.08 | ||||
| White | 136 (69.0) | 50 (61.0) | – | Reference | |
| Black | 47 (23.9) | 19 (23.2) | 0.17 | 0.568 [0.253–1.289] | |
| Other§ | 14 (7.1) | 13 (15.9) | <0.01 | 0.275 [0.106–0.709] | |
| Body mass index (kg/m2), mean ± SE | 31.2 ± 0.6 | 30.6 ± 1.0 | 0.58 | – | – |
| Hypertension, n (%) | 135 (68.5) | 59 (72.0) | 0.57 | – | – |
| Diabetes mellitus, n (%) | 72 (36.6) | 31 (37.8) | 0.84 | – | – |
| Dyslipidemia, n (%) | 93 (47.2) | 34 (41.5) | 0.38 | – | – |
| Metabolic syndrome, n (%) | 73 (37.1) | 32 (39.0) | 0.77 | – | – |
| Cancer type | 0.64 | – | – | ||
| Gastrointestinal, n (%) | 83 (42.1) | 40 (48.8) | – | – | |
| Soft tissue, n (%) | 57 (28.9) | 20 (24.4) | – | – | |
| Genitourinary, n (%) | 34 (17.3) | 11 (13.4) | – | – | |
| Other, n (%) | 23 (11.7) | 11 (13.4) | – | – | |
| Serum laboratory values | |||||
| Alanine aminotransferase (U/L), mean ± SE | 28.7 ± 1.6 | 63.1 ± 5.1 | <0.01 | <0.01 | 0.633 [0.523–0.735]* |
| Aspartate aminotransferase (U/L), mean ± SE | 24.6 ± 0.7 | 66.3 ± 5.1 | <0.01 | – | – |
| Total bilirubin (mg/dL), mean ± SE | 0.69 ± 0.03 | 0.94 ± 0.11 | 0.04 | 0.02 | 0.618 [0.414–0.889]† |
| Alkaline phosphatase (U/L), mean ± SE | 92.4 ± 4.3 | 142.4 ± 15.6 | <0.01 | 0.05 | 0.927 [0.849–0.997]‡ |
| Albumin (mg/dL) | 3.57 ± 0.05 | 3.43 ± 0.08 | 0.14 | – | – |
| Creatinine (mg/dL), mean ± SE | 0.89 ± 0.02 | 0.96 ± 0.05 | 0.22 | – | – |
| Hemoglobin (g/dL), mean ± SE | 12.4 ± 0.1 | 11.8 ± 0.3 | 0.04 | 0.19 | 1.056 [0.973–1.147]¥ |
| Hematocrit (%), mean ± SE | 37.1 ± 0.4 | 35.1 ± 0.7 | <0.01 | – | – |
| Platelets (thousand/μL), mean ± SE | 277.6 ± 8.5 | 191.6 ± 9.7 | <0.01 | – | – |
| Diagnostic radiologic imaging | 0.20 | – | – | ||
| Computed tomography, n (%) | 187 (94.9) | 73 (89.0) | – | ||
| Ultrasound, n (%) | 8 (4.1) | 7 (8.5) | – | ||
| Magnetic resonance imaging, n (%) | 2 (1.0) | 2 (2.4) | – | ||
| Chemotherapy treatment | 75 (38.1) | 42 (51.2) | 0.04 | <0.01 | 0.366 [0.184–0.708] |
Multivariable analysis for the end point of low probability of fibrosis is included
SE standard error, APRI AST-to-platelet ratio index
§
Includes Hispanic, Native American, and Asian populations
Units:
*
10 U/L;
†
0.5 mg/dL;
‡
20 U/L;
¥
0.5 g/dL